THMO: ThermoGenesis Holdings Inc. Fair Value Consensus

ThermoGenesis focuses on expanding the supply of cell culture and umbilical cord blood separation systems through long-term agreements with biobanks. The business relies on the creation of automated complexes for the cryopreservation and separation of stem cells, which eliminates routine manual labor. The linear price action on the chart, where the indicator is 4.99, complements data regarding the company's partnerships with biomaterial storage therapy centers.

This indicator represents an aggregated fair value assessment of the asset, stripped of market volatility and subjective management forecasts. The trend in analysts' median target price reflects market confidence in the scaling of the PXP system fleet and the growth of revenue from ancillary consumables, which allows for the determination of the fundamental resilience of ThermoGenesis (THMO) within the biobanking segment.